GHK-Cu + TB-500 + BPC-157; Glow Blend explained: what's in this research peptide stack, how the three compounds differ, dosing math, and safety caveats.
The Glow Blend is a research peptide stack that combines GHK-Cu, TB-500, and BPC-157 in a single lyophilized vial. It is a vendor-made convenience product for laboratory work, not an approved drug, supplement, or cosmetic, and it has not been reviewed by the FDA for human use. Each of the three peptides is studied separately, and the blend itself has almost no dedicated published research.
Understanding the blend means separating the three compounds and looking at what the science actually says about each one. That is what the rest of this guide does.
What the Glow Blend Is — and What It Isn't
"Glow Blend" is a marketing name, not a scientific or regulatory category. The label usually appears on vials sold by research chemical suppliers who combine three popular peptides into one product to reduce the number of vials a buyer needs to reconstitute.
It is not:
- A clinically validated combination — the three peptides have never been tested together in a controlled human trial.
- A topical "glow" cosmetic — despite the name and the presence of GHK-Cu, a blend vial is a lyophilized powder, not a skincare product.
- An FDA-approved drug — no version of this stack is approved for any human indication.
Vendors pitch the format as cost-effective and easy to handle. Researchers point out that a blended vial makes it impossible to attribute an observed effect to a single compound.
What's Inside: GHK-Cu, TB-500, and BPC-157
Formulations are not standardized, and the ratio varies from one supplier to the next. A widely seen configuration is 50 mg of GHK-Cu, 10 mg of TB-500, and 10 mg of BPC-157, for 70 mg of total powder.
| Component | Chemical identity | Typical amount per blend vial | Primary research focus |
|---|---|---|---|
| GHK-Cu | Copper tripeptide-1 (glycyl-L-histidyl-L-lysine bound to copper) | 50 mg | Collagen synthesis, skin remodeling, wound healing in cell and animal models |
| TB-500 | Synthetic fragment of thymosin beta-4 | 5–10 mg | Cell migration, actin regulation, and blood vessel formation in animal studies |
| BPC-157 | Pentadecapeptide BPC 157 (a 15-amino-acid sequence) | 5–10 mg | Gastrointestinal protection and tendon or ligament healing in rodent models |
GHK-Cu accounts for roughly 70 percent of the mass in a 50/10/10 blend. That is the main reason the product carries a "glow" name, since copper peptides have a long history in topical cosmetic research.
How the Three Components Differ in Research
The three peptides are not variations on one theme. They act on different pathways and are studied for different endpoints.
- GHK-Cu is studied mainly in skin and connective tissue models and appears in cosmetic formulations as a topical ingredient. Systemic exposure to a copper peptide is a different question entirely.
- TB-500 is examined in animal models of cell migration and tissue remodeling. Human clinical data are essentially absent, so one of the most common questions, is tb-500 safe, still has no confident answer.
- BPC-157 has the largest preclinical literature of the three, mostly in rodents. The popular search does bpc-157 help with muscle growth is not well supported by that literature, which focuses on gut lining protection, tendon healing, and similar repair endpoints rather than muscle hypertrophy.
Blending them does not create synergy data. No published study has isolated a combined effect of GHK-Cu, TB-500, and BPC-157 administered together.
Dosing Math, Ratios, and Reconstitution
A blended vial cannot be dosed as one compound. When a vial holds three peptides at different masses, every dose calculation has to be done per component.
In animal research, BPC-157 is typically dosed by body weight rather than by a fixed amount. Any bpc-157 dosage per body weight figure therefore has to be expressed in micrograms per kilogram and then adjusted for the fraction of the vial that is actually BPC-157.
| Component | Mass in a 70 mg vial | Concentration per mL after adding 3 mL of diluent | Share of total powder |
|---|---|---|---|
| GHK-Cu | 50 mg | ~16.7 mg/mL | ~71% |
| TB-500 | 10 mg | ~3.3 mg/mL | ~14% |
| BPC-157 | 10 mg | ~3.3 mg/mL | ~14% |
Basic Handling Steps
- Let the lyophilized vial reach room temperature before opening it.
- Swab the stopper, then add bacteriostatic or sterile water slowly down the inside wall of the vial.
- Swirl gently. Do not shake, because shaking can damage peptide structure.
- Store unreconstituted vials frozen and reconstituted vials refrigerated, protected from light.
- Expect some color change in GHK-Cu solutions over time because of the copper content.
Rodent-to-human dose conversions are rough estimates, not clinical guidance. No regulatory body has established a human dose for this blend or for any of its parts.
Oral vs Injectable Research Formats
Format can matter as much as the peptide. The comparison of bpc-157 tb-500 oral vs injection comes down to stability and bioavailability, and the two compounds behave differently.
BPC-157 appears relatively stable in gastric conditions in animal work, which is why capsules and oral solutions are common. TB-500 and GHK-Cu have far less oral data, and copper peptides are more often studied topically than systemically.
The Glow Blend itself is sold as a lyophilized powder intended for laboratory reconstitution. Oral products marketed under similar names usually contain a single peptide and should not be assumed to deliver the amounts listed on a blend label.
Safety, Legality, and Buying Considerations
None of these peptides is approved for human use in the United States. "Research use only" labeling is a legal disclaimer, not a safety statement.
Injectable products from unregulated sources carry real risks, including contamination, incorrect concentration, and unknown purity. Copper-containing peptides add a further concern, because excess copper is genuinely toxic.
Anti-doping agencies prohibit all three peptides for competitive athletes. Possession and personal use may also conflict with state and federal rules depending on how a product is labeled and sold.
Researchers who ask where to buy bpc-157 and tb-500 should start with third-party purity testing, a lot-specific certificate of analysis, and a supplier willing to answer questions about synthesis and sterility. Even then, quality varies widely between vendors.
The bottom line: the Glow Blend is an unapproved research combination with no dedicated clinical evidence. Anyone considering these compounds for personal use should talk with a licensed healthcare professional first.
RELATED PEPTIDE TOPICGHK-Cu researchFrequently Asked Questions
What is the Glow Blend peptide stack?
The Glow Blend is a single vial that combines GHK-Cu, TB-500, and BPC-157 in a lyophilized powder sold for research use. It is a vendor-created combination rather than a formulation evaluated in clinical trials, and a common ratio is 50 mg GHK-Cu, 10 mg TB-500, and 10 mg BPC-157.
Is the GHK-Cu, TB-500, and BPC-157 blend FDA approved?
No. None of the three peptides is FDA-approved for human use, and the combination itself has never been reviewed by the agency. Products sold as Glow Blend are labeled for laboratory research only, which is a legal disclaimer rather than a safety endorsement.
How do you dose a Glow Blend vial?
Dosing has to be calculated per peptide, not per vial, because the three components are present in very different amounts. A 70 mg vial reconstituted with 3 mL of diluent yields roughly 16.7 mg/mL of GHK-Cu and about 3.3 mg/mL each of TB-500 and BPC-157, and no established human dose exists for any of them.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.